| Sucampo Pharma Europe, a subsidiary of Sucampo Pharmaceuticals, announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza, lubiprostone, 24 microgram gel capsules for the long-term treatment of patients with chronic idiopathic constipation, or CIC. This is the first European regulatory approval for Sucampo and Amitiza is the first prescription medicine to be approved in Switzerland for the long-term treatment of CIC. Amitiza is already approved by the U.S. FDA for the long-term treatment of CIC in adults and for the treatment of irritable bowel syndrome with constipation, or IBS-C, in adult women. Amitiza is the only prescription medicine approved by the FDA for either of these indications. :theflyonthewall.com |
